Pallavi S Mishra-Kalyani

FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non‐Small Cell Lung Cancer: First‐Line Therapy and Beyond

K. Goldberg, P. Keegan, Amy McKee, 2017, The oncologist.

Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer.

S. Khozin, K. Goldberg, R. Pazdur, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma

L. Fashoyin-Aje, R. Pazdur, A. Cortellini, 2023, JHEP reports : innovation in hepatology.

FDA Approval Summary: Nivolumab in Combination with Ipilimumab for the Treatment of Unresectable Malignant Pleural Mesothelioma

Jiang Liu, Martha Donoghue, R. Pazdur, 2021, Clinical Cancer Research.

Global Variation in Opioid Use in Prostate Cancer Trials.

R. Pazdur, J. Roydhouse, G. Blumenthal, 2019, JAMA Oncology.

Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice.

K. Goldberg, R. Pazdur, L. Rimassa, 2021, European journal of cancer.

FDA Accelerated Approval of Pembrolizumab for Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma.

P. Keegan, R. Pazdur, S. Lemery, 2020, The oncologist.

FDA analyses of survival in older adults with metastatic non-small cell lung cancer in controlled trials of PD-1/PD-L1 blocking antibodies.

P. Keegan, R. Pazdur, G. Blumenthal, 2018, Seminars in oncology.